Genting's 4Q Earnings Likely to Remain Flat On-Quarter

1
1
Favorite

Genting's 4Q Earnings Likely to Remain Flat On-Quarter

Dow Jones11-29

Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. (yingxian.wong@wsj.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

AcidIce
·11-29
Whatever is said is no use, because people loves to gamble. Then money will just come in regardless. Just buy in more when it's cheap, then wait. It will go up.
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2487321376?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-29 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2487321376","market":"sg","top_or_hot":-1,"title":"Genting's 4Q Earnings Likely to Remain Flat On-Quarter","media":"Dow Jones","content":"<p>Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. (yingxian.wong@wsj.com)</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genting's 4Q Earnings Likely to Remain Flat On-Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenting's 4Q Earnings Likely to Remain Flat On-Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-29 09:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"G13.SI","symbol_name":"云顶新加坡","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2487321376","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2487321376","pubTimestamp":1732842960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0116 GMT - Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"G13.SI":"云顶新加坡"},"translate_title":"云顶第四季度盈利可能与季度持平","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"G13.SI":0.9},"content_text":"Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. (yingxian.wong@wsj.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":376213707227224,"gmtCreate":1732850768596,"gmtModify":1732850772962,"author":{"id":"3569382039983887","authorId":"3569382039983887","name":"AcidIce","avatar":"https://static.tigerbbs.com/25a5edd325094826cf6e8822874786ab","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3569382039983887","authorIdStr":"3569382039983887"},"htmlText":"Whatever is said is no use, because people loves to gamble. Then money will just come in regardless. Just buy in more when it's cheap, then wait. It will go up.","listText":"Whatever is said is no use, because people loves to gamble. Then money will just come in regardless. Just buy in more when it's cheap, then wait. It will go up.","text":"Whatever is said is no use, because people loves to gamble. Then money will just come in regardless. Just buy in more when it's cheap, then wait. It will go up.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/376213707227224","repostId":2487321376,"repostType":2,"repost":{"id":"2487321376","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1732842960,"share":"https://ttm.financial/m/news/2487321376?lang=&edition=fundamental","pubTime":"2024-11-29 09:16","market":"sg","language":"en","title":"Genting's 4Q Earnings Likely to Remain Flat On-Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2487321376","media":"Dow Jones","summary":"0116 GMT - Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. ","content":"<p>Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. (yingxian.wong@wsj.com)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genting's 4Q Earnings Likely to Remain Flat On-Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenting's 4Q Earnings Likely to Remain Flat On-Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-29 09:16</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. (yingxian.wong@wsj.com)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"G13.SI":"云顶新加坡"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2487321376","content_text":"Genting's 4Q Ebitda is expected remain flat sequentially, as seasonally lower visitor arrivals at Genting Singapore may be offset by seasonally higher visitors in Genting Malaysia, Maybank IB analyst Yin Shao Yang says in a note. The company's next potential catalysts are the anticipated approval of its 20%-owned associate TauRx Pharmaceuticals' experimental drug next month and a potential win of a full New York casino license next year, he adds. Yin cuts Genting's 2024-2026 earnings forecasts by 27%, 23% and 21%, respectively. Maybank lowers Genting's target price to MYR4.48 from MYR5.83, after its 3Q earnings missed expectations. It maintains a buy rating on the stock. Shares are 0.3% higher at MYR3.76. (yingxian.wong@wsj.com)","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}